Taotlus

SILLAMÄE LINNAVALITSUS Erkki Keldo Majandus- ja tööstuminister [email protected] Pärt-Eo Rannap Peadirektor [email protected] Teie: Meie: 28.04.2026 a nr 12-3/749-1 TAOTLUS Lugupeetud härra majandus- ja tööstusminister, Lugupeetud härra peadirektor, Õiglase ülemineku mehhanismi eesmärk on toetada üleminekut kliimaneutraalsele majandusele. Eestis on õiglase ülemineku keskmes Ida-Virumaa, kus suure majandusliku ja keskkonnaalse mõjuga ning suure hõivatusega põlevkivitööstusest loobumise tõttu tuleb leida lahendusi keskkonnaprobleemide lahendamisele, tööstusharu asendava võimalikult suure lisandväärtusega tootmise ja ettevõtluse arendamisele ning elukeskkonna parandamisele. Selleks on õiglase ülemineku vahenditest ette nähtud võimalused toetada innovaatilisi ettevõtlusprojekte. Meie hinnangul on põlevkivitööstuse asendamisel oluline majanduse mitmekesistamine ning seejuures võimalikult suure lisandväärtusega ja innovatiivsed projektid, mille rahastamiseks on keeruline leida teisi toetusmeetmeid. Sillamäe linn on arengukavas ette näinud vajaduse toetada GENECODE biotehnoloogia ja ravimiarenduse projekti. GENECODE AS on registreeritud aadressil Sillamäe Kesk 1b. GENECODE AS innovatiivne ettevõte, mis on spetsialiseerunud biotehnoloogiliste lahenduste Kesk 27, 40231 Sillamäe [email protected] Tel +372 392 5700 www.sillamae.ee 2 väljatöötamisele ja patenteerimisele. Ettevõttel on kõrgelt kvalifitseeritud meeskond ning projekti jaoks vajalikud patendid. GeneCode on Eesti ravimite arendamise ettevõte, mis keskendub ravimeetodite väljatöötamisele neurodegeneratsiooni vastu võitlemiseks. Ettevõte on loonud GDNF-i mimeetikumide platvormi, mis kasutab gliiarakkude päritoluga neurotroofse faktori (GDNF) haigust modifitseerivaid omadusi ning rakendab neid väikemolekulidele, millel on ravimilaadsed omadused. GeneCode on Euroopa juhtiva biotehnoloogia uudisteportaali Labiotech poolt koostatud Eesti seitsme silmapaistvama biotehnoloogiaettevõtte nimekirjas. GeneCode on silma paistnud oma tootearendusprogrammiga, mis hõlmab ravimikandidaate selliste haiguste vastu nagu amüotroofne lateraalskleroos (ALS), retiniit pigmentoosa (RP), põletikuline soolehaigus (IBD) ja Parkinsoni tõbi (PD). Need ravimikandidaadid on loodud haiguse progresseerumise aeglustamiseks, soodustades närvirakkude ellujäämist ja funktsiooni. Põlevkivikeemia ja eriti põlevkivi peenkeemia alase tootmise ja arendamise alase potentsiaali äralangemisel on kohane ära kasutada sellekohaseid teadmisi ja kogemusi suure tulevikupotentsiaaliga biotehnoloogia rahvusvahelise tipptasemega arenduse ja tootmisega seotud investeeringuteks. Ajalooliselt on Sillamäe linn loodud kohapealse keemiatehase tarvis, millele 1950-60 lisandus elanikkond, mis põhines ümbruskonna põlevkivitööstuse töötajatel, nii et ligikaudu pool linna elanikest oli seotud otseselt põlevkivitööstusega. Ka täna kui räägitakse Narva karjäärist või teistest põlevkiviettevõtetest, siis olenevalt ettevõtetest töötab seal tegelikult oluline hulk Sillamäe elanikke (Narva karjääris näiteks 95% töötajatest). Leiame, et eeltoodud projekti oleks võimalik rahastada õiglase ülemineku vahenditest, kui raha vabaneb nende projektide arvelt, mis erinevatel põhjustel ei realiseeru. Lugupidamisega /allkirjastatud digitaalselt/ Tõnis Kalberg linnapea lisad: projekti esildis ning projektide infomaterjalid IDA-VIRUMAA MAJANDUSE IDA-VIRUMAA ÕIGLASE ÜLEMINEKU FONDI RAAMES ÜMBERKUJUNDAMISEST Projekti esildis Nii üldise m aailma majanduselu kui ka keskkonna- ning sotsiaalelu korraldamises ning riikidevahelistes majandusliku ning poliitilise koostöö korraldamises on objektiivsetel põhjustel toimumas suured ja põhimõttelised ni ng p raktiliselt kõiki riike, kogukondi ning inimesi puudutavad kardinaalsed muudatused, mis loomulikult puudutavad ka Eestit ning Eestisiseselt eriti teravalt Ida-Virumaad, sealhulgas ka Sillamäed. Maailmas on pidevalt suureneva majandustegevuse mahu tõttu k eskkonnale/kliimale ohtlikuks muutumas fossiilsete maavarade väga oluline keskkonda saastav, sealhulgas ka maakera keskmist temperatuuri kriitiliselt tõstev vastutustundetu ning ebaefektiivsete tehnoloogiatega toimuv soojusenergia tootmine. Selles osas on ka rahvusvahelises mastaabis kõnekaks näiteks Ida-Virumaal p õlevkivi põhilise kodumaise kütteainena kasutav e nergeetika -e lektrienergia ja s oojusenergia tootmine. Paraku aga juba nii Eestis tervikuna ning ka Ida-Virumaal käimasolev e nergiatootmise üleviimine CO2 suhtes neutraalse taastuvenergia – p äikese - ja t uuleenergia kasutamisele pole lihtsalt tehnilis -majanduslik küsimus, vaid on seotud väga laialdaselt ka sotsiaalse valdkonnaga – kaovad ära põlevkivi kasutamise valdkondadega nii otseselt kui kaudselt seotud töökohad, taastuva p äikese- ja t uuleenergia põhjal on küll tehnoloogiliselt lihtne toota elektrit (juhul kui on sobivalt nii t uult kui p äikest), kuid see protsess on ilmastiku piisavalt täpse ennustamatuse tõttu mitte juhitav, ja salvestamine on küllaltki kallis. Ka ei saa fossiilset põlevkivi energiaallikana kasutavatest kütteseadmetest erinevalt ajaliselt ja mahuliselt täpselt etteennustamatute näitajatega p äikseenergiaga või t uuleenergiaga tekitada kortermajade kütmiseks vajalikku kortermajade sooja kaugküttevee soojust, mille puudumine mõjutaks kriitiliselt enamiku Ida-Virumaa elanike elukvaliteeti. Ja sellele kõigele ülaltoodule lisandub veel ka käesoleval ajal toimuv üleüldine elanikkonna vanananemine – kiiresti suurenev vajadus nii vanurite hooldajate kui täiendavate kallite hooldekodude/hooldekodude lisakohtade ning kallite lisateenuste järele. Mitmete ülaltoodud ülikriitilistele probleemidele kas olulist leevendust või põhimõttelisi lahendusi toovate initsiatiivide osas on Sillamäe linnale tulnud väga suurt kontseptuaalset huvi pakkuv ning Ida-Virumaa Õiglase Ülemineku Fondi raames Sillamäe linna ja Sillamäe linna poolse võimaliku vahendamise võimalustega ka Ida-Virumaa teistele piirkondadele potentsiaalselt laiendatavate kõrgtehnoloogiliste p rojektide investeeringute toomise kompleks s ed ettepanekud. Käsitluse all olevad kriitilistesse ja ümberprofileerimist vajavatesse majandusvaldkondadesse pakutavad suurinvesteeringute ettepanekud on esitatud Sillamäele algselt juba üle 2 aasta tagasi ning neid on Sillamäel erinevatele auditooriumitele ka aktiivselt esitatud, kuid täna on need sisuliselt üliolulised Ida-Virumaa Õiglase Ülemineku Fondi raames teha kavatsetavate suurinvesteeringute pakkumised jäänud Õiglase Ülemineku Fondi Projektide loetelusse lülitamata . Käesolevaga taotle me nimetatud projektide – Energiasäästlike Kinnisvaraprojektide põhiprojekti (1994.a. moodustatud Tallinna WTC) Intellektuaalomandi toodava oskusteabe ning investeeri n gutega ning Põlevkivi (peen)keemiat Ravimiarenduse suuna peenkeemiale ümberprofileerimist kavandava ( GeneCode AS, moodustatud 1993.a.) Intellektuaalomandi ning põhiliselt rahvu s vaheliste suurinvesteeringute toomist pakkuvate projektide Ida-Virumaa Õiglase Ülemineku Fondi lülitamist. Nimetatud mõlema kahe suuna ko m plekssed infomaterjalide kompleksid on lisatud täiendavalt. Oluliseks täiendavaks taustafaktiks nende projektide osas lisaks sellele, et nad on üldteadaolevalt edukalt üle kolme aastakümne edukalt toiminud, on ka see, et nende projektide käivitaja, arendaja ning võtmetähtsusega suuromanik, Dr. Mehis Pilv – teaduste doktor Rakendusküberneetika valdkonnas – nii nimetati 1984.a. Doktoridissertatsiooni kaitsmise ajal praegu Tehisintellektiks nimetatavat teadusvaldkonda – on ka mitmete oma kõrgtehnoloogiliste suurprojektide realiseerimise poolest hästi tuntud nii Sillamäel kui ka Ida-Virumaal laiemalt. Mõned näited – 1980. aastate esimeses pooles arvutiklasside jaoks salajases Narva Baltiijetsi tehases JUKU arvutite tootmine, mille tähtsust Eesti varajase digikompetentsi saavutamisel on võimatu alahinnata, 1990.a. esimesel poolel ülisaastava Kunda Tsemenditehase USA Tehnilise abi ja rahastusega rek o nstrueerimise ning loomulikult Sillamäe Uraani/Haruldaste Muldmetallidega tehase Eesti omanikele toonud äriplaani l ä biviijana aastast 1997. Lisaks äriprojektide vedajana võttis Dr. Mehis Pilv osa linna ettevõtluse esindajana ka Sillamäe linnavalituse tööst ning on tunnustatud linnavolikogu poolt. GENECODE Development of Disease-modifying Treatment for Neurodenerative Diseases  GDNF Mimetics Development History 1996 2009 2021 Jan. 2022 Sep. 2022 Feb. 2023 RET, BT13 In vivo target Improvement Start of lead First cpds with First cpd, showing identified GDNF engagement of motor optimization same level of both brain as the receptor with BT13 function in rat with Serge efficacy as penetration after oral GDNF agonist (intracranial) 6-OHDA with Mignani GDNF in vitro admin. and receptor identification BT44 neuroprotection (intracranial) in vitro 1. GDNF mimetic for Parkinson’s management. Mahato et al., 2020. 2. GDNF receptor RET agonist for PD. Renko et al., 2021. March 2023 June 2023 July 2023 Aug. 2023 Jan. 2024 March 2025 March 2026 March 2027 Neuroprotection EAR993 3 new EAR911 IND/CTA- IND enabling Phase 1a / Phase 2a show in human showing improved patents filed showing higher enabling studies DA neurons metabolic stability neuroprotection (EAR586, and brain penetra- than GDNF in EAR685) tion (MDCK) human DA neurons Neurotrophic Factors and Parkinson’s Disease Patients with Parkinson's disease: • Progressive neurodegenerative • 1% of people over the age of 65 are disorder developing Parkinson's disease • Degeneration and loss of • 10 million patients worldwide have been diagnosed with PD, with this number dopamine neurons is expected to double by 2040 associated with motor and non-motor symptoms of • Economic Burden (US 2017) = $51B PD • Motor symptoms are partially addressed but no disease-modifying drug exists to protect or restore dopamine neurons • No treatment for non- motor symptoms Growth factors do not only protect but also Neurotrophic factors are an attractive restore degenerating neurons, promote target for supportive and neuro- arborization and sprouting of their neurites, restorative therapeutic approaches and enhance their functional activity Sidorova and Saarma TIPS, 2020; Mahato AK and Sidorova YA. Cell Tissue Res. 2020 3 Neurotrophic Effects of GDNF Revealed in Patients with PD • 21 per group, with mid-stage PD, all receiving four catheters and port (new design) Core Treatment Details • Infusion every 4 weeks for 40 weeks (GDNF-240 ug or vehicle) then all patients are rolled over into an open-label all active (40 weeks) • Primary efficacy outcome not statistically significant (UPDRSIII in OFF time) Efficacy Summary • Improvements in good “ON time” over baseline (will be the primary endpoint for future trials) • Biological effect demonstrated by PET Imaging. Expert: Prof. Jon Stoessl 4  Finding Small Molecule with same MOA as GDNF GDNF family ligands GDNF and NRTN activate GFRα-RET receptors Targeting GDNF receptors with promoting survival and regenerating axons of dopamine neurons in small molecules neurotoxin animal models of PD 5 EAR911 activates GDNF signalling pathways via RET receptor LUCIFERASE ASSAY DIRECT RET PHOSPHORYLATION ASSSAY 6 EAR911- Mouse PO pharmakokinetics Formulation: 10 % DMSO, 10 % Solutol H15, 40% PEG 200, 40 % 0.01% Tween 80 in 10 mM Tris buffer pH8 7 EAR911 protects both wild-type and α-synuclein mutated human dopamine neurons from neurotoxin-induced cell death Wild-type Human Dopamine Neurons α-synuclein A53T-Mutated Human Dopamine Neurons 8 EAR911 penetrates blood-brain barrier and increases dopamine release 9 Systemic delivery of EAR911 improves motor coordination and motor learning in rotarod test in the MPTP-Probenecid mouse model of Parkinson’s disease 10 EAR911 rescues gastrointestinal tract dysfunction in the MPTP-Probenecid mouse model of Parkinson’s disease 11  From biological concept to small-molecule drug EAR911 GDNF BT13 EC50 = 5 nM (Neuroprotection) EC50 = 5 nM EC50 = 13000 nM Efficacy= 100% Efficacy= 100% Efficacy= 10% Active in patients Active in patients Active in rodents models of Parkinsons’s disease Neuroprotection in human dopamine Intraputaminal administration Intraputaminal administration neurons, penetrates BBB and stimulates dopamine release, improves both motor and non-motor symptoms in MPTP model of PD 12  Take-Home Message • EAR911 penetrates BBB and stimulates dopamine release • EAR protects and regenerates human iPSC-derived wild-type and α-synuclein mutated dopamine neurons • EAR911 in mouse model of Parkinson’s disease improves global motor behavior of mice • Most importantly, systemically delivered EAR911 dramatically reduced constipation and normalized the function of gastrointestinal tract (GIT) • Currently, we are analyzing the brain tissues from MPTP study by immunohistochemistry 13  Possible Targets of GDNF Mimetics • Successfully continuing PD development means that GeneCode has a wide range of potential follow-up activities based on the GDNF Mimetics platform development. • Our preliminary studies indicate that the 3 most promising indications are: Amyotrophic Lateral Sclerosis (ALS), Retinitis Pigmentosa (RP), and Inflammatory Bowel Disease (IBD). • As a proof of concept, we have started studying GDNF mimetics both in vitro and in vivo model of ALS, RP and IBD 14  . Neurotrophic factors and Amyotrophic lateral sclerosis ( ALS ) • ALS is fatal neurodegenerative disease affecting both upper and lower motor neurons • The progressive loss of motor neurons causes rapid loss of motor control, leading to paralysis and death within 3-5 years of symptom onset • Glial cell line-derived neurotrophic factor (GDNF) has the potential to support the survival and maintenance of motor neurons with 100 times more efficacious than other trophic factors • A recent Phase I/II safety study was conducted by transplanting human progenitor cells (hNPCs) engineered to produce and secrete GDNF unilaterally to the lumbar spinal cord. In this safety trial, the primary endpoint of safety was met, and the results from postmortem tissues grafted cells survived and produced GDNF • The second clinical trial is underway to evaluate the cortical delivery of hNPCs-GDNF 15  Neurotrophic factors and Inflammatory bowel disease (IBD) • IBD is a term for two conditions Crohn's disease (CD) and ulcerative colitis (UC) and is characterized by chronic inflammatory process of patient’s gut • Disruption of intestinal epithelium layer is a semi permeable physical barrier might play role in the development and progression of IBD • GDNF and its receptors are significantly expressed in intestine and play important role regulating epithelia tight junction in the intestinal epithelial barrier (IEB) and protect intestinal cell invasion from bacterial infection • GDNF also acts as anti-inflammatory agent in murine models of colitis • Recent finding indicate that GDNF was significantly reduced in IBD patients Patients with IBD: with CD and UC, indicating disease-relevant contribution to the development of IEB dysfunction • About 4 million females and 3 million males are living with IBD worldwide and cases is on rise • Our recent finding shows that GDNF mimetics recues gastrointestinal • The prevalence of IBD was reported to range dysfunction which indicates that GDNF mimetics can be drug for IBD from 252 to 439 cases per 100 000 population in the USA. 16  Neurotrophic factors and Retinitis pigmentosa (RP) • RP is a group of inherited disorders characterized by HEALTHY RETINA RETINITIS PIGMENTOSA the progressive dysfunction of predominantly rod followed by cone photoreceptor cells • GDNF receptors are predominantly expressed in retinal ganglionic cells as well as in Müller cells of the retina • Both in vitro as well as in vivo studies show that GDNF promotes the survival of photoreceptor and ganglionic cells after injury • Recently, subretinal injection hNPCs-GDNF has Patients with Retinitis Pigmentosa: shown significant neuroprotection and enables the • The worldwide prevalence of retinitis pigmentosa is about 1 in 4000 for a extended survival of photoreceptor cells in total of more than 1 million affected individuals. transplanted animal eyes • Currently, there are no treatment available to stop the disease progression and restore the vision • Phase I/IIa clinical trial of transplanting hNPCs- GDNF into the subretinal space of RP patients is • As a proof of concept, we are studying GDNF mimetic in both in vitro and in ongoing vivo models of RP 17 Development Overview An Estonia-based biotech company focused on developing small molecule GDNF mimetics with the potential for disease-modifying treatments for nervous system disorders Drug Development HQ in Tallinn, Estonia Team of 20+ EUR 14.2m Funding to date Launch 2007 GeneCode is developing novel small molecule GDNF mimetics Management Team with the potential for disease-modifying treatments for nervous system disorders Genecode’s lead compounds for PD will enter the IND phase in 2024 Pre-clinical Trials IND Phase Clinical Trials finalized in 2024 2024-2025 2025+ Paavo Pilv, EMBA Prof. Dr. Mart Saarma Prof. Dr. Tarmo Tamm CEO, Partner CSO, Partner Lead Scientist The annual listing of 10 companies in the EU that are at the forefront of Patents x3 x1 providing Drug Discovery and Development solutions, impacting the industry in the region Key Partners: EUR 14.3m Equity investment commitment from EIC 18 Core Team Dr. Mehis Pilv, The Company Founder Prof. Dr. Mart Saarma, Research Director and Professor at the Institute of Biotechnology, University of Helsinki, Sr Partner of GeneCode, CSO, JMC member of Kevad Bio Paavo Pilv, EMBA, CEO of GeneCode, JMC member of Kevad Bio Prof. Dr. Tarmo Tamm, University of Tartu, lead scientist of GeneCode Arun Mahato, PhD, Institute of Biotechnology, University of Helsinki, lead scientist of GeneCode Yves Ribeill, PhD, Partner, Entrepreneur-In-Residence, Co-founder of Argobio Studio, JMC member of Kevad Bio Delphine Charvin, PhD, Operating Partner at Argobio Studio, JMC member of Kevad Bio Mélanie Rouillier, MSc, PMP, Scientific Project Manager at Argobio Studio Serge Mignani, PhD, Consultant in Medicinal Chemistry for Argobio Studio Timeline Building a Valuable Pipeline Discovery Lead Op Preclinical IND Ph I Ph II Ph III KB-001 (GFRɑ1-RET) Neuro-protection and restoration in PD KB-xxx (GFRɑ1-RET) 3 new indications: ALS, RP, IBD Weight loss Other Addiction diseases Today Ahead of Series A 20 Market analyses Building a Valuable Pipeline Indication Patients Compound Market value Future market annual growth value rate (CAGR) PD Over 10 million 14,5% Global market $7,1 billion by worldwide value 2022 $3.4 2029 billion ALS 4-6 cases per 13,9% $282 million in Exceed $1.04 100,000 2019 within the 8 billion by 2029 individuals MM RP Affects 7,3% Global market $20.33 billion by approximately 1 value 2021 $11.57 2029 in every 3,000 billion IBD 6-8 million 5,7% Global market $37 billion by individuals value 2022 $25.18 2029 worldwide billion 21 ARE WE TALKING ABOUT A POTENTIAL NEW UNICORN? Existing drugs are generic and have very similar treatment Parkinson's Disease - Deal Comparables: Segmented by Stage paths. The GeneCode drug is the first one that restores the of Development neurons affected by PD. $M The strategy is to secure a strategic corporate partnership with an Upfront payment Milestone payment Total deal value industry-leading pharmaceutical company. The core takeaway 1 200 from the deal/transaction comparable analysis shown here is that 1 000 800 there are multiple key time points where GeneCode can expect 600 to secure a corporate partnership (i.e., preclinical, Phase 1, 2, 400 3). 200 Discovery Preclinical Phase 1 Phase 2 Phase 3 The main drive behind these very lucrative financial deals is innovative PD drug treatments offering ‘disease-modifying’ abilities. GeneCode is developing novel PD therapies that also have this important attribute of disease-modifying potential. Contact Paavo Pilv E-mail: [email protected] CEO Mobile: +372 50 20 111 GENECODE Paavo Pilv [email protected] E-mail: [email protected] CEO [email protected] Mobile: +372 50 20 111 WTC Tallinn Ltd WORLD TRADE CENTRE® planned renovation TALLINN WTC TALLINN is located in the city centre, between the Old Town, the airport and the port, which serves 12-13 million passengers per year. WTC Tallinn is the largest privately owned and privately operated office spaces offering company in the Nordic-Baltic region. WTC Tallinn recently celebrated its 30th year of successful operations.  Forming of THE WTC TALLINN LTD in 15.04.1994 Starting date of dinator for Central the WTC Tallinn and Eastern Europe Development Pro- of the Industrializ- ject is known very ing Nations Com- precicely – 15th of mittee of the WTCA April 1994. That day Mr. Guenter Ehring, formed for that pur- Director of the WTC pose and leaded by RUHR VALLEY. Dr. Mehis Pilv In- With prepearing the vestment Company WTC Tallinn WTCA RET Development Membership deci- Group LTD bought sion worked also on the public auc- Mr. Matthew Kleink- tion the pancropthed Tallinn Radielectron- necht from the WTCA HQ and among others ic Plant (RET) big Industrial Quarter in the also Vice President and Secretary General of Tallinn City Centre. the WTCA Mr. Tom Kearney. The WTC Tallinn Taking care of the highly attractive location in WTCA Membership Application was Supported the Tallinn City Centre, his buildings, proper- by the WTCA Board Meetings, by 1995 WTCA ties and the infrastructure, this big Industrial Spring Meeting in Mexico and WTCA General Quarter was decided to convert to the big In- Assembly in Beijing and the WTC Trade mark ternational Business Quarter and to apply for it was granted to the WTC Tallinn on April 24, the brand name “World Trade Center Tallinn“. 1995. One of the most prominent Estonian Architects Ambitious and innovative use by companys Mr. Raine Karp made the shown here the first management the various competive advan- arhitectual version of this planned to be devel- tages of this Big Private Tallinn WTC Quarter oped Tallinn Big International Business Quarter had made the WTC Tallinn Project from the and the Application Documents for getting the very beginning selfsufficient and ecomically Tallinn World Trade Center brand name were very profitable during all of the more then 30 sent to the World Trade Centers Association years of its succesful operations. (WTCA) HQ in New York. Starting in 2025 the new full Reconstruction of The RET Development Group WTC Tallinn the WTC Tallinn Business Quarter can also be Brand name Application was in WTCA HQ characterized by using of many very ambitious well accepted and the prepearing of the cor- and innovative newest technologies, from responding WTCA Membership decicion outstanding and flexible modern architectual documentation was delecated to the Chair- solutions to the AI controlled best possible in- man of the Industrializing Nations Committee door climate for users. The buildings with best of the WTCA, Mr. K.H. Wu of WTC Taipei. possible energy performance are engineered In connection of defining the various local, to be zero emission buildings (ZEB) and they related to the Applicant questions, Tallinn was will harvest renewable heating and cooling visited by the appointed by the WTCA repre- energy with geothermal heat pump with effec- sentatives – many times by the Regional Coor- tive thermal storage in the ground. 2  Crucial for occupants comfort air condition- ing and ventilation systems are silent oper- ation, low velocities and high level of ther- mal comfort and Indoor Air Quality (IAQ ), for that will be used a low-pressure ventilation ductwork of combined air conditioning and heat recovery demand-controlled ventilation system. Very important are also many unic flexible architectual-constructoral technological solu- tions, which will be also described in more. DETAILS All those newest ambitious arhitectural – constructoral - technological solutions with using newest high efficiency AI software will be described more precicely in the next parts of this manual. Also is very important to un- derline, that thanks to very high efficiency of the technological solutions of many WTC Tal- linn Quarter infrastructure systems, some ser- vices can be additionally to the clients of the own WTC Quarter be very profitable deliv- ered also to the neighboring properties – for example central heat and cooling, electrical energy, parking places, connections to public Tallinn International Electronics transport et cetera. and Trade Center Architect Raine Karp sketch project from 1994 Borders the harbor area 3  WTC Tallinn development team WTC Tallinn’s ambitious reconstruction project is ensured by the use of top professionals from various fields. DR. MEHIS PILV has a Ph.D. in Applied Computer Sciences, more than 20 publications on radio-electronics, applied cybernetics and international entrepreneur- ship and more than 10 inventions and patents. Dr. Pilv is the founder of WTC Tallinn Ltd. He is also the founder GENE- CODE and is a significant investor and business developer. He is a private owner of the World Trade Center, Tallinn and also has inter- ests in many significant real estate projects. https://genecode.com/team/mehis-pilv/ The globally ambitious architectural solution has been developed by Professor Andres Alver, who is the developer of the architectural solu- tions for many of the new developments in Tallinn. Such as the Roter- mann Center, Krulli Quarter, Smuuli tee Quarter, and so on. PROF. DR. ANDRES ALVER has taught at the Estonian Academy of Arts (formerly ERKI) since 1985. Since 2006, he has been a full professor. He has worked as a visiting pro- fessor at the College of Architecture of the Virginia Polytechnic Institute (Alexandria, VA) and at the Faculty of Architecture of the private university RISEBA in Riga, and has been a visiting critic at the Department of Archi- tecture of Umea University (Sweden) and the School of Design of Harvard University (Cambridge, MA). www.ata.ee The construction of the WTC Tallinn quarter is being provided by Estonia’s leading construction company MERKO. The renewable geothermal energy from the WTC Tallinn territory is provided by MAAKÜTE LTD (Geothermal heat energy). 4 The most important innovative solution for the reconstructed WTC is to power the new quarter with 100% renewable energy all year round. The corresponding direction has been developed by Professor Jarek Kurnitski of Tallinn University of Technology and Professor Robert Kitt, Head of Utilitas. PROF. DR. JAREK KURNITSKI is Professor at Tallinn University of Technology, Estonia, and at Aalto Uni- versity, Finland. He is internationally renowned for preparation of techni- cal definitions for nearly zero energy buildings through many activities in REHVA and European standardisation. www.etis.ee/CV/Jarek_Kurnitski/ The ambitious architecture is complemented by one of Estonia’s leading design offices, Disainikorp, with its innovative design solutions. MA. KAREL KORP Karel Korp is an Estonian designer, illustrator, book designer and painter. Graduated from Tallinn University with a degree in art education and drawing. In 1997, he founded the advertising and design agency Disaini- korp, which is one of the oldest operating design agencies in Estonia. He has collaborated with the Bank of Estonia, the Financial Supervision Authority, the Chancellor of Justice, the Employers’ Confederation, the Chamber of Commerce and Industry, the Estonian Cooperation Council, the World Trade Center Tallinn and many other institutions and compa- nies. He has created trademarks and corporate graphics for international- ly operating companies. He has participated in dozens of exhibitions with his illustrations and paintings both in Estonia and elsewhere in the world. From 2016 to the present, he has been the chairman of the Estonian Graphic Designers’ Association and one of the owners of the illustration gallery TINT. www.disainikorp.ee 5  Zero Emission Building and optimal Indoor Environmental Quality targets in WTC Tallinn In addition to the striking and unique architectural design, the building’s CO2 footprint and its unique solution based on 100% renewable geothermal and solar energy should also be noted. This is described in more detail on the following page. 6 WTC Tallinn Business Quarter with Zero Emission and optimal Indoor Environment office and living buildings Certified to the highest level of LEED/ triple glazing. Four pane windows with clear BREEAM/WELL should not only demonstrate low-emission glazing offer superior thermal in- modern architecture but also to offer best sulation and solar protection at the same time possible indoor climate for users. An opti- while visible light transmittance can reach 60% mal Indoor Environmental Quality (IEQ ) is of- that is well enough for facades having high ten overlooked in value engineering, but it window to wall ratios because of sea views deserves efforts for better user satisfaction, and other architectural reasons. The drawback wellbeing and productivity. In WTCT this goes of four panel glazing are higher weight and a hand in hand with best possible energy per- challenge for profile systems to have a space formance as these buildings aim to be zero for more than 70 mm thick glazing units. De- emission buildings (ZEB) and beyond before pending on energy prices such solution can be an official definition of ZEB even exists. There cost effective in the long run and WTCT wants are the following three innovative elements to to be a forerunner focusing to life cycle cost achieve ZEB and optimal IEQ targets in WTCT. instead of investment cost. 1. 3. WTCT buildings located in city centre will Air conditioning and ventilation systems are harvest renewable energy with semi deep crucial for occupant’s comfort. WTCT pre- boreholes and photovoltaic on-site electric- fers silent operation, low velocities and sys- ity generation. Because of limited size of the tems operating on demand to provide high building site a common borehole in Estonian level of thermal comfort and Indoor Air Qual- soil conditions of 50 m will be replaced with ity (IAQ ). A low-pressure ventilation ductwork much deeper one. Ongoing experimental drill- of combined air conditioning and heat recov- ing aims to reach about 600 m with three test ery demand-controlled ventilation system will boreholes which then will enable to conduct a be used. This system sized for terminal unit thermal response test to provide design data pressure drop has lower velocities and static for the entire borehole field. It is expected pressure in the ductwork than usually making that boreholes with a geothermal heat pump it flexible and robust for demand control op- will supply most of the heating and cooling of eration even with simple on-off type of damp- buildings and enable effective thermal storage ers. WTCT aims to design one of the first air in the ground. The rest of heating and cooling conditioning and ventilation systems in Esto- energy will be covered with effective district nia having IAQ regulation and monitoring that heating and cooling. is one important feature of future ZEBs. Such design makes IEQ visible for users and bene- 2. fits from utilising passive features but will take more space because of larger ducts. However, careful architectural design and high ceilings To reduce heating and cooling loads, highly performing façade would be needed. As lo- in WTCT turn this to be a reasonable solution cated in cold climate, facades with four pane maximising both energy and IEQ performance. glazing units are studied instead of common 7  Parda T1 (internal street) 2024 m2 In the quarter, which has a total of 20,000 m2 of plot area and 100,000 m2 of building area, all buildings are accessible by car from various directions. The street is also wide enough to allow access to the first- floor commercial buildings by commercial vehicle. Public transport options are located in the immediate vicin- ity of the quarter, which directly connect the port and the airport. 8  ◀ PORTO FRANCO REIDI ROAD ▶ AHTRI STREET Parda T1 (internal street) 2024 m2 Ahtri 8 Ahtri 12 Parda 12 Parda 9 JÕE STREET Jõe 9 Parda 10 Parda 8 Jõe 7 apartment building Parda 7 Parda 6 Jõe 5A apartment building Parda 5 Jõe 5 Parda 3 Parda 4 Jõe 3 ◀ ROTERMANN QUARTER Narva 9 Narva 11 Parda T1 (internal street) 2 024 m2 • 100% WTC NARVA ROAD 9  Parda T1 (internal street) 10 11 12 13  WTC Tallinn quarter WTC Tallinn quarter compared Tallinn’s passenger port is around ½ a kilometer away, the city’s main rail- to the neighboring Rotermann way station is around 3 kilometers business district away, and Tallinn Airport is around 4 kilometers away. 14  Rotermann quarter Town Hall Square in the Old Town is around View from Tallinn Town Hall Square 2 kilometers away. Starting from this summer, you will be able to take the tram from the harbour directly to the main entrance of the WTC. 15  Parda 9, Ahtri 8/12, Jõe 9 towers reconstructed buildings Upper floor general plan. Gross floor area 3307 m2 View of the projecting part of the apartment 16 132.3 m2 118.4 m2 17  Parda 9, Ahtri 8/12, Jõe 9 towers reconstructed buildings Upper floor general plan. Gross floor area 3307 m2 View of the projecting part of the apartment 18 Apartments on the upper floors of Ahtri 8-12 88.9 m2 82.3 m2 19  Parda street 3, 5, 7 towers According to the detailed plan, the construction of both offices and living spaces is secured. 167 m2 931 m2 107 m2 209 m2 99 m2 1:1 tenant on the floor 2:3 tenant on the floor 20 The three towers above at Parda 3, 5 and The three described office buildings are 7 are multifunctional buildings with plan- designed to conform to the class A stand- ning permits for both office and residen- ard, which means zero-energy buildings tial space. A sufficient number of parking in terms of energy consumption. The lo- spaces has been provided for both. The cation of the office buildings in the WTC towers are planned to be 11-storey build- Tallinn quarter provides a significant com- ings with a height of 38.5 m. petitive edge. Technical data of the Parda • No. of floors: 11 street 3, 5, 7 three properties: • Gross area: 19 077m2 • Area available for • Net area: 17 309m2 construction: 2 294m2 • Parking spaces: 222 21 22 The figure below shows a multifunctional The building was designed to be an energy building extending onto the pedestrianised efficiency class A structure, i.e. a nearly zero Ahtri Street, the main part of which is an ex- energy building with the best available ener- clusive projecting section resting on a braid- gy efficiency and renewable energy technol- ed pipe. Here, too, there will be both office ogy. and residential spaces with sufficient parking. WTC Tallinn Ltd Collaboration and investment proposals: Ahtri 8, 10151 Tallinn, Estonia Mehis Pilv, member of the board of WTC Tallinn Phone: +372 626 1001 Phone: +372 50 31 801 E-mail: [email protected] • www.wtc.ee E-mail: [email protected] [email protected] 23  THE TALLINN WTC QUARTER designed by Professor Andres Alver according to the zoning plan from 2010, with updates starting from 2025 Additional PORTO connection REIDI ROAD FRANCO to the WTC Parda T1 Quarter (internal street) 2 024 m2 • 100% WTC Ahtri 8/12 – 23 810 m2 (Current enclosed net area 11 432 m2, according to Ahtri 8 the zoning plan 23 810 m2, AHTRI STR. Ahtri 12 WTC part 93.43%) Property area JÕE STR. 2 977 m2 Parda 9 – 14 950 m2 Current enclosed net area 9 960 m2, Jõe 9 – 2 925 m2 according to the zoning plan 14 950 m2 Parda 12 Property 100% WTC Parda 9 Current enclosed net area 295 m2 Jõe 9 Property area area 881 m2 710 m2 Parda 10 Property Property area Current area 2 172 m2 240 m2 enclosed net area 720 m2 Additional access to the Parda 8 Current WTC Quarter enclosed net area 2 831 m2 Property area Jõe 7 1 406 m2 apartment Property building Parda 3, 5, 7 area 905 m2 Current DELFI enclosed net 19 020 m2 area 8 633 m2 QUARTER 100% WTC Parda Current enclosed 6 Jõe 5A Parda 3, 5, 7 net area 2 617 m2, Current apartment building according to the enclosed zoning plan 19 020 m2 net area Current enclosed net Property area 1 946 m2 area 4 050 m2 901 m2 Parda 7 property area 908 m2 Property Jõe 5 area Parda 5 property 539 m2 Current Property area enclosed 543 m2 area 1 037 m2 net area Parda 3 property 1 999 m2 area 931 m2 Parda 4 Building managed Parda 4 Jõe 3 by WTC 3 745 m2 Current 100% WTC enclosed net area Property area 3863 m2 740 m2 Property area 1 276 m2 Narva 9 Narva 11 Property area 1 739 m2 Current enclosed ROTERMANN net area 7 869 m2 QUARTER Parda T1 (internal street) 2 024 m2 • 100% WTC NARVA ROAD One of Tallinn’s busiest roads Area of buildings owned by Area of buildings operated by Area of the buildings WTC Quarter WTC Quarter in the quarter 68 313 m2 30 965 m2 TOTAL: 99 278 m2 or approx. 1 million square feet Area of the properties Area of the properties Total area owned by WTC 12 775 m2 operated by WTC 6 568 m2 of the properties 19 343 m2 Saatja: [email protected] Saaja: "info - MKM" <[email protected]>, "Info - RTK" <[email protected]> Teema: [DKIM katki]Taotlus Kuupäev: 2026-04-28 06:08 Tähelepanu! Tegemist on välisvõrgust saabunud kirjaga. Tundmatu saatja korral palume linke ja faile mitte avada. HOIATUS! See e-kiri võib olla liba-, õngitsus- või pahaloomuline, kuna on saadetud asutusest, kus meiliserver on vigaselt seadistatud. Rohkem infot: KKK | teenusveeb <https://teenused.rit.ee/et/kkk> -> E-post ja kalender. Tere! Teile on saadetud Sillamäe Linnavalitsuse dokumendihaldussüsteemi Delta kaudu dokument Taotlus, mis on registreeritud 28.04.2026, numbriga 12-3/749-1. Dokument avaneb DigiDoc Client programmi abil, mille saab arvutisse tasuta alla laadida kodulehelt https://installer.id.ee/ Kontaktinfo Sillamäe Linnavalitsus Kesk 27, Sillamäe Tel: +372 39 25 700 e-post: [email protected] <mailto:[email protected]>